GLP1R and diabetes mellitus: Previous research has shown that most patients with diabetes who would benefit from evidence-based medications to reduce the risk of cardiovascular related mortality were not prescribed an SGLT-2 inhibitor or a GLP-1 agonist [3,4,5].